8-KEarnings & ResultsLeadership ChangesExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 21, 2016)

Filed July 21, 2016For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on July 21, 2016, announcing its second-quarter financial results and a significant leadership change. The company reported its financial performance for the quarter ended June 30, 2016, details of which were provided in an accompanying press release furnished as an exhibit. This filing is crucial for investors to assess the company's operational performance and financial health during the period.

Key Highlights

  • 1Biogen reported its second-quarter 2016 financial results on July 21, 2016.
  • 2The financial results were detailed in a press release furnished with the 8-K filing.
  • 3George A. Scangos, Ph.D., will step down as Chief Executive Officer (CEO).
  • 4Dr. Scangos will continue to serve as CEO until a successor is identified.
  • 5Dr. Scangos will remain on the Board of Directors even after stepping down from his executive role.
  • 6The Board of Directors has immediately commenced a search for a new CEO.
  • 7The filing does not constitute a formal filing under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings.

Frequently Asked Questions

The 8-K filing states that Biogen announced its second-quarter financial results for the period ended June 30, 2016. The specific details of these results, such as revenue, net income, and earnings per share, were provided in a press release furnished as Exhibit 99.1.

George A. Scangos, Ph.D., announced his intention to step down as Chief Executive Officer. He will continue in his role until a successor has been identified. Biogen's Board of Directors has initiated an immediate search for his replacement.

Yes, Dr. Scangos will remain on Biogen's Board of Directors until he steps down from his executive position as CEO. This suggests a potential for continued guidance and a smooth transition.

When information is 'furnished' under Item 2.02, it means it's provided to the SEC for informational purposes but is not subject to the same legal liabilities as 'filed' information under Section 18 of the Securities Exchange Act of 1934. It also means it is not automatically incorporated into other SEC filings like the Securities Act of 1933 or the Exchange Act unless explicitly stated.